An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations AndroMETa-Lung-536

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT06772623

Study #:
STUDY00161997

Start Date:
Mar 19, 2026

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06772623

View Complete Trial Details & Eligibility at ClinicalTrials.gov